Matthew Barcus
Stock Analyst at Chardan Capital
(2.38)
# 2,575
Out of 4,976 analysts
21
Total ratings
25%
Success rate
21.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $2.21 | +352.49% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $17.43 | +54.91% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.70 | +906.18% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $16.37 | +95.48% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.60 | +36,627.88% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.98 | +202.01% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $9.40 | -14.89% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $2.21
Upside: +352.49%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $17.43
Upside: +54.91%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.70
Upside: +906.18%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $16.37
Upside: +95.48%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.60
Upside: +36,627.88%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.98
Upside: +202.01%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $9.40
Upside: -14.89%